Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activation

OncoImmunology

Volumn 6, Issue 4, 2017, Pages

  Veinalde, Rūta ^a   Grossardt, Christian ^a   Hartmann, Laura ^a   Bourgeois Daigneault, Marie Claude ^b,c   Bell, John C ^b,c   Jäger, Dirk ^a   von Kalle, Christof ^a   Ungerechts, Guy ^a,b   Engeland, Christine E ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Anti PD L1; cancer immunotherapy; interleukin 12; measles virus; Oncolytic viruses

Indexed keywords

INTERLEUKIN 12; MEASLES VACCINE; ONCOLYTIC VIRUS;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CELL VIABILITY ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; MEASLES VIRUS; MEDICAL PROCEDURES; NONHUMAN; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; UPREGULATION;

EID: 85017124160     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2017.1285992     Document Type: Article

References (43)

1. Bell, J, McFadden, G. Viruses for tumor therapy. Cell Host Microbe 2014; 15:260-5; PMID:24629333; http://dx.doi.org/10.1016/j.chom.2014.01.002
2. Pol J, Buqué A, Aranda F, Bloy N, Cremer I, Eggermont A, Erbs P, Fucikova J, Galon J, Limacher JM, et al. Trial watch-oncolytic viruses and cancer therapy. Oncoimmunology 2016; 5:e1117740; PMID:27057469; http://dx.doi.org/10.1080/2162402X.2015.1117740
3. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses:a new class of immunotherapy drugs. Nat Rev Drug Discov 2015; 14:642-62; PMID:26323545; http://dx.doi.org/10.1038/nrd4663
4. Donnelly OG, Errington-Mais F, Steele L, Hadac E, Jennings V, Scott K, Peach H, Phillips RM, Bond J, Pandha H, et al. Measles virus causes immunogenic cell death in human melanoma. Gene Ther 2013; 20:7-15; PMID:22170342; http://dx.doi.org/10.1038/gt.2011.205
5. Miyamoto S, Inoue H, Nakamura T, Yamada M, Sakamoto C, Urata Y, Okazaki T, Marumoto T, Takahashi A, Takayama K, et al. Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. Cancer Res 2012; 72:2609-21; PMID:22461509; http://dx.doi.org/10.1158/0008-5472.CAN-11-3185
6. Diaconu, I, Cerullo V, Hirvinen ML, Escutenaire S, Ugolini M, Pesonen SK, Bramante S, Parviainen S, Kanerva A, Loskog AS, et al. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Res 2012; 72:2327-38; PMID:22396493; http://dx.doi.org/10.1158/0008-5472.CAN-11-2975
7. Angelova AL, Grekova SP, Heller A, Kuhlmann O, Soyka E, Giese T, Aprahamian M, Bour G, Rüffer S, Cziepluch C, et al. Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer. J Virol 2014; 88:5263-76; PMID:24574398; http://dx.doi.org/10.1128/JVI.03688-13
8. Guillerme, JB, Boisgerault N, Roulois D, Ménager J, Combredet C, Tangy F, Fonteneau JF, Gregoire M. Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells. Clin Cancer Res 2013; 19:1147-58; PMID:23339127; http://dx.doi.org/10.1158/1078-0432.CCR-12-2733
9. Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer 2014; 14:559-67; PMID:24990523; http://dx.doi.org/10.1038/nrc3770
10. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015; 33:2780-88; PMID:26014293; http://dx.doi.org/10.1200/JCO.2014.58.3377
11. Russell SJ, Peng KW. Measles virus for cancer therapy. Curr Top Microbiol Immunol 2009; 330:213-41; PMID:19203112
12. Grossardt, C, Engeland CE, Bossow S, Halama N, Zaoui K, Leber MF, Springfeld C, Jaeger D, von Kalle C, Ungerechts G. Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine. Hum Gene Ther 2013; 24:644-54; PMID:23642239; http://dx.doi.org/10.1089/hum.2012.205
13. Engeland CE, Grossardt C, Veinalde R, Bossow S, Lutz D, Kaufmann JK, Shevchenko I, Umansky V, Nettelbeck DM, Weichert W, et al. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol Ther 2014; 22:1949-59; PMID:25156126; http://dx.doi.org/10.1038/mt.2014.160
14. van de Laar L, Coffer PJ, Woltman AM. Regulation of dendritic cell development by GM-CSF:molecular control and implications for immune homeostasis and therapy. Blood 2012; 119:3383-93; PMID:22323450; http://dx.doi.org/10.1182/blood-2011-11-370130
15. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3:133-46; PMID:12563297; http://dx.doi.org/10.1038/nri1001
16. Homey B, Muller A, Zlotnik A. Chemokines:agents for the immunotherapy of cancer? Nat Rev Immunol 2002; 2:175-84; PMID:11913068; http://dx.doi.org/10.1038/nri748
17. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://dx.doi.org/10.1038/nrc3239
18. Haile ST, Dalal SP, Clements V, Tamada K, Ostrand-Rosenberg S. Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression. J Immunol 2013; 191:2829-36; PMID:23918985; http://dx.doi.org/10.4049/jimmunol.1202777
19. Robbins PF, Kantor JA, Salgaller M, Hand PH, Fernsten PD, Schlom J. Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. Cancer Res 1991; 51:3657-62; PMID:1712245
20. Hammond AL, Plemper RK, Zhang J, Schneider U, Russell SJ, Cattaneo R. Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. J Virol 2001; 75:2087-96; PMID:11160713; http://dx.doi.org/10.1128/JVI.75.5.2087-2096.2001
21. Nakamura T. Peng KW, Harvey M, Greiner S, Lorimer IA, James CD, Russell SJ. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol 2005; 23:209-14; PMID:15685166; http://dx.doi.org/10.1038/nbt1060
22. Vincent S, Tigaud I, Schneider H, Buchholz CJ, Yanagi Y, Gerlier D. Restriction of measles virus RNA synthesis by a mouse host cell line:trans-complementation by polymerase components or a human cellular factor(s). J Virol 2002; 76:6121-30; PMID:12021345; http://dx.doi.org/10.1128/JVI.76.12.6121-6130.2002
23. Ungerechts G, Springfeld C, Frenzke ME, Lampe J, Parker WB, Sorscher EJ, Cattaneo R. An immunocompetent murine model for oncolysis with an armed and targeted measles virus. Mol Ther 2007; 15:1991-97; PMID:17712331; http://dx.doi.org/10.1038/sj.mt.6300291
24. Schwarz AJ. Preliminary tests of a highly attenuated measles vaccine. Am J Dis Child 1962; 103:386-9; PMID:13909753
25. Combredet, C, Labrousse V, Mollet L, Lorin C, Delebecque F, Hurtrel B, McClure H, Feinberg MB, Brahic M, Tangy F. A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. J Virol 2003; 77:11546-554; PMID:14557640; http://dx.doi.org/10.1128/JVI.77.21.11546-11554.2003
26. Chen DS, Mellman I. Oncology meets immunology:the cancer-immunity cycle. Immunity 2013; 39:1-10; PMID:23890059; http://dx.doi.org/10.1016/j.immuni.2013.07.012
27. Shin, EJ, Wanna GB, Choi B, Aguila D, 3rd, Ebert O, Genden EM, Woo SL. Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma. Laryngoscope 2007; 117:210-4; PMID:17204993; http://dx.doi.org/10.1097/01.mlg.0000246194.66295.d8
28. Bortolanza, S, Bunuales M, Otano I, Gonzalez-Aseguinolaza G, Ortiz-de-Solorzano C, Perez D, Prieto J, Hernandez-Alcoceba R. Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters. Mol Ther 2009; 17:614-22; PMID:19223865; http://dx.doi.org/10.1038/mt.2009.9
29. Derubertis, BG, Stiles BM, Bhargava A, Gusani NJ, Hezel M, D'Angelica M, Fong Y. Cytokine-secreting herpes viral mutants effectively treat tumor in a murine metastatic colorectal liver model by oncolytic and T-cell-dependent mechanisms. Cancer Gene Ther 2007; 14:590-97; PMID:17431402; http://dx.doi.org/10.1038/sj.cgt.7701053
30. Colombo MP, Trinchieri, G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13:155-68; PMID:11900991; http://dx.doi.org/10.1016/S1359-6101(01)00032-6
31. Lieschke, GJ, Rao, PK, Gately, MK, Mulligan, RC. Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo. Nat Biotechnol 1997; 15:35-40; PMID:9035103; http://dx.doi.org/10.1038/nbt0197-35
32. Gately MK, Desai BB, Wolitzky AG, Quinn PM, Dwyer CM, Podlaski FJ, Familletti PC, Sinigaglia F, Chizonnite R, Gubler U, et al. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 1991; 147:874-82; PMID:1713608
33. Brunda, MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF, Gately MK. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993; 178:1223-30; PMID:8104230; http://dx.doi.org/10.1084/jem.178.4.1223
34. Kodama, T, Takeda K, Shimozato O, Hayakawa Y, Atsuta M, Kobayashi K, Ito M, Yagita H, Okumura K. Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12. Eur J Immunol 1999; 29:1390-96; PMID:10229107; http://dx.doi.org/10.1002/(SICI)1521-4141(199904)29:04%3c1390::AID-IMMU1390%3e3.0.CO;2-C
35. Smyth MJ, Taniguchi M, Street SE. The anti-tumor activity of IL-12:mechanisms of innate immunity that are model and dose dependent. J Immunol 2000; 165:2665-70; PMID:10946296; http://dx.doi.org/10.4049/jimmunol.165.5.2665
36. Mlecnik, B, Bindea G, Kirilovsky A, Angell HK, Obenauf AC, Tosolini M, Church SE, Maby P, Vasaturo A, Angelova M, et al. The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. Sci Transl Med 2016; 8:327ra326; PMID:26912905; http://dx.doi.org/10.1126/scitranslmed.aad6352
37. Chang, J, Cho JH, Lee SW, Choi SY, Ha SJ, Sung YC. IL-12 priming during in vitro antigenic stimulation changes properties of CD8 T cells and increases generation of effector and memory cells. J Immunol 2004; 172:2818-26; PMID:14978082; http://dx.doi.org/10.4049/jimmunol.172.5.2818
38. Medina-Echeverz J, Fioravanti J, Zabala M, Ardaiz N, Prieto J, Berraondo P. Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. J Immunol 2011; 186:807-15; PMID:21148040; http://dx.doi.org/10.4049/jimmunol.1001483
39. Calain P, Roux L. The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA. J Virol 1993; 67:4822-30; PMID:8392616
40. Radecke F, Spielhofer P, Schneider H, Kaelin K, Huber M, Dötsch C, Christiansen G, Billeter MA. Rescue of measles viruses from cloned DNA. Embo J 1995; 14:5773-84; PMID:8846771
41. Martin A, Staeheli P, Schneider U. RNA polymerase II-controlled expression of antigenomic RNA enhances the rescue efficacies of two different members of the Mononegavirales independently of the site of viral genome replication. J Virol 2006; 80:5708-15; PMID:16731909; http://dx.doi.org/10.1128/JVI.02389-05
42. Andersen CL, Jensen JL, Orntoft TF. Normalization of real-time quantitative reverse transcription-PCR data:a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 2004; 64:5245-50; PMID:15289330; http://dx.doi.org/10.1158/0008-5472.CAN-04-0496
43. Amsen D, de Visser KE, Town T. Approaches to determine expression of inflammatory cytokines. Methods Mol Biol 2009; 511:107-42; PMID:19347295; http://dx.doi.org/10.1007/978-1-59745-447-6_5